Innovation for Accessibility and Market Reach

Zorzouve, formerly known as Brexenalone, developed by Sage Therapeutics for postpartum depression, was a scientific breakthrough but faced challenges in accessibility and market success due to its cumbersome delivery method and high cost. With the approval of Zorelone, an oral version of the drug, Sage aims to cater to a wider market by providing a more accessible and user-friendly treatment option for postpartum depression.